OTC · SONX
Sonendo, Inc.
$1.28$0.00 (0.0%)
Sonendo, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.63% below the high.
Loading market information…
OTC · HTDS · USD
Stock price
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Hard to Treat Diseases Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Hard to Treat Diseases Inc. (HTDS), founded in 2009 and headquartered in Shenzhen, China, is a pharmaceutical firm engaged in the development, manufacturing, and global export of biopharmaceutical products and vaccines. The company's extensive portfolio includes a range of biological agents such as reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection. HTDS also provides various chemical pharmaceuticals, including cobratide injection, entecavir capsules, HES, dasatinib tablets, thymosin a1 for injection, imipenem and cilastatin sodium for injection, and meropenem for injection. Additionally, it supplies critical vaccines for rabies, ACYW135 meningococcal disease, influenza, Hepatitis A, and varicella. HTDS distributes its offerings through a sales network primarily focused on markets in South Asia, Southeast Asia, Central and South America, and the Middle East.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
$1.28$0.00 (0.0%)
Sonendo, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.63% below the high.
$0.00$0.00 (0.0%)
IR Biosciences Holdings Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
GlobeStar Therapeutics Corporation: Healthcare · Biotechnology.
$0.00$0.00 (0.0%)
Mobile Lads Corp.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.01$0.00 (0.0%)
Panbela Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.56% below the high.
$0.00$0.00 (0.0%)
GB Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.98% below the high.
$0.01$0.00 (0.0%)
Adastra Holdings Ltd.’s quoted price sits in the lower half of its reported 52-week range, 65.0% below the high.
$0.00$0.00 (0.0%)
Ehouse Global, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
